Cargando…

Drug delivery options to increase patient adherence and satisfaction in the management of rheumatoid arthritis – focus on subcutaneous tocilizumab

Rheumatoid arthritis (RA) is a chronic, progressive, inflammatory disease associated with joint destruction. Tocilizumab (TCZ) is a humanized monoclonal anti-interleukin-6 receptor antibody that was initially developed for use as an intravenous (IV) infusion. Previous studies have shown that TCZ-IV...

Descripción completa

Detalles Bibliográficos
Autores principales:	Nakashima, Yasuharu, Kondo, Masakazu, Miyahara, Hisaaki, Iwamoto, Yukihide
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2014
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4094568/ https://www.ncbi.nlm.nih.gov/pubmed/25045250 http://dx.doi.org/10.2147/DDDT.S52099

Ejemplares similares

Characteristics of lumbar scoliosis in patients with rheumatoid arthritis
por: Ohishi, Masanobu, et al.
Publicado: (2014)

Refining the Management of Rheumatoid Arthritis: the Benefits of Subcutaneous Tocilizumab
por: Negoescu, Andra F., et al.
Publicado: (2014)

Phase III Study of the Efficacy and Safety of Subcutaneous Versus Intravenous Tocilizumab Monotherapy in Patients With Rheumatoid Arthritis
por: Ogata, Atsushi, et al.
Publicado: (2014)

Safety and tolerability of subcutaneous sarilumab and intravenous tocilizumab in patients with rheumatoid arthritis
por: Emery, Paul, et al.
Publicado: (2019)

Th1 is the predominant helper T cell subset that produces GM-CSF in the joint of rheumatoid arthritis
por: Yamada, Hisakata, et al.
Publicado: (2017)

Early intervention in the treatment of rheumatoid arthritis: focus on tocilizumab
por: Yilmaz, Sedat, et al.
Publicado: (2013)

Mid-term clinical results of primary total knee arthroplasty using metal block augmentation and stem extension in patients with rheumatoid arthritis
por: Hamai, Satoshi, et al.
Publicado: (2015)

Sustainable Efficacy of Switching From Intravenous to Subcutaneous Tocilizumab Monotherapy in Patients With Rheumatoid Arthritis
por: Ogata, Atsushi, et al.
Publicado: (2015)

Accelerated subcutaneous nodulosis in patients with rheumatoid arthritis treated with tocilizumab: a case series
por: Talotta, Rossella, et al.
Publicado: (2018)

Subcutaneous Tocilizumab Versus Placebo in Combination With Disease-Modifying Antirheumatic Drugs in Patients With Rheumatoid Arthritis
por: Kivitz, Alan, et al.
Publicado: (2014)

Efficacy of subcutaneous tocilizumab in patients with rheumatoid arthritis and systemic sclerosis overlap syndrome: a report of two cases and review of the literature
por: Wakabayashi, Hiroki, et al.
Publicado: (2019)

Management of rheumatoid arthritis in People’s Republic of China – focus on tocilizumab and patient considerations
por: Wang, Geng, et al.
Publicado: (2015)

Review of tocilizumab in the treatment of rheumatoid arthritis
por: Okuda, Yasuaki
Publicado: (2008)

Tocilizumab in the treatment of rheumatoid arthritis and beyond
por: Shetty, Anjali, et al.
Publicado: (2014)

Tocilizumab: A Review in Rheumatoid Arthritis
por: Scott, Lesley J.
Publicado: (2017)

Factors affecting patient satisfaction related to cost and treatment effectiveness in rheumatoid arthritis: results from the multicenter observational cohort study, FRANK Registry
por: Fujiwara, Toshifumi, et al.
Publicado: (2022)

Potential patient benefit of a subcutaneous formulation of tocilizumab for the treatment of rheumatoid arthritis: a critical review
por: Besada, Emilio
Publicado: (2014)

Impact of tocilizumab administered intravenously or subcutaneously on patient-reported quality-of-life outcomes in patients with rheumatoid arthritis
por: Strand, Vibeke, et al.
Publicado: (2018)

Effects of concomitant glucocorticoids in TOZURA, a common-framework study programme of subcutaneous tocilizumab in rheumatoid arthritis
por: Choy, Ernest, et al.
Publicado: (2019)

Tocilizumab Effectiveness After Switching from Intravenous to Subcutaneous Route in Patients with Rheumatoid Arthritis: The RoSwitch Study
por: Darloy, Jean, et al.
Publicado: (2019)

Safety and Efficacy of Tocilizumab for the Treatment of Rheumatoid Arthritis
por: Ogata, Atsushi, et al.
Publicado: (2012)

Longitudinal immunomonitoring following Tocilizumab in rheumatoid arthritis
por: Pers, Yves-Marie, et al.
Publicado: (2011)

Cardiac Tamponade During Tocilizumab Therapy in a Patient with Rheumatoid Arthritis and Anti-DNA Antibody Positivity
por: Miyahara, Daisuke, et al.
Publicado: (2021)

Pharmacokinetic and Pharmacodynamic Analysis of Subcutaneous Tocilizumab in Patients With Rheumatoid Arthritis From 2 Randomized, Controlled Trials: SUMMACTA and BREVACTA
por: Abdallah, Hisham, et al.
Publicado: (2016)

Predictive Factors for Rheumatoid Arthritis Flare After Switching From Intravenous to Subcutaneous Formulation of Tocilizumab in Real-World Practice
por: Ahn, Soo Min, et al.
Publicado: (2022)

Subcutaneous Sarilumab in Patients With Rheumatoid Arthritis who Previously Received Subcutaneous Sarilumab or Intravenous Tocilizumab: An Open‐Label Extension of a Randomized Clinical Trial
por: Emery, Paul, et al.
Publicado: (2020)

Hepatotoxicity of tocilizumab and anakinra in rheumatoid arthritis: management decisions
por: Mahamid, Mahmud, et al.
Publicado: (2011)

Malignancy rates in patients with rheumatoid arthritis treated with tocilizumab
por: Rubbert-Roth, Andrea, et al.
Publicado: (2016)

Tocilizumab-Induced Dermatosis in a Patient With Rheumatoid Arthritis
por: Babkoor, Doaa, et al.
Publicado: (2022)

Subcutaneous tocilizumab in rheumatoid arthritis: findings from the common-framework phase 4 study programme TOZURA conducted in 22 countries
por: Choy, Ernest, et al.
Publicado: (2018)

Subcutaneous tocilizumab in rheumatoid arthritis: findings from the common-framework phase 4 study programme TOZURA conducted in 22 countries
por: Choy, Ernest, et al.
Publicado: (2018)

Efficacy and safety of subcutaneous tocilizumab in rheumatoid arthritis over 1 year: a UK real-world, open-label study
por: Isaacs, John D, et al.
Publicado: (2019)

Pharmacokinetics and Pharmacodynamics of Subcutaneous Sarilumab and Intravenous Tocilizumab Following Single‐Dose Administration in Patients With Active Rheumatoid Arthritis on Stable Methotrexate
por: Paccaly, Anne J., et al.
Publicado: (2020)

Subcutaneous dosing regimens of tocilizumab in children with systemic or polyarticular juvenile idiopathic arthritis
por: Ruperto, Nicolino, et al.
Publicado: (2021)

Subcutaneous abatacept for the treatment of rheumatoid arthritis
por: Schiff, Michael
Publicado: (2013)

Critical appraisal of tocilizumab in the treatment of moderate to severe rheumatoid arthritis
por: Hushaw, Linda L, et al.
Publicado: (2010)

Tocilizumab: A Review of Its Safety and Efficacy in Rheumatoid Arthritis
por: Jones, Graeme, et al.
Publicado: (2010)

Current perspectives on tocilizumab for the treatment of rheumatoid arthritis: a review
por: Al-Shakarchi, Israa, et al.
Publicado: (2013)

Efficacy and safety of tocilizumab in Korean patients with active rheumatoid arthritis
por: Baek, Han Joo, et al.
Publicado: (2019)

Progressive Multifocal Leukoencephalopathy during Tocilizumab Treatment for Rheumatoid Arthritis
por: Anada, Mamiko, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_r81m0ddocsocctkqql59lttstt